These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18855660)

  • 1. Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs.
    Chan DJ; Ray JE; McNally L; Batterham M; Smith DE
    Curr HIV Res; 2008 Sep; 6(5):477-84. PubMed ID: 18855660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between HIV-RNA load in blood and semen in antiretroviral-naïve and experienced men and effect of asymptomatic sexually transmissible infections.
    Chan DJ; McNally L; Batterham M; Smith DE
    Curr HIV Res; 2008 Mar; 6(2):138-42. PubMed ID: 18336261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
    Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
    HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
    Ghosn J; Chaix ML; Peytavin G; Bresson JL; Galimand J; Girard PM; Raffi F; Cohen-Codar I; Delfraissy JF; Rouzioux C
    J Antimicrob Chemother; 2008 Jun; 61(6):1344-7. PubMed ID: 18343806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma.
    Lorello G; la Porte C; Pilon R; Zhang G; Karnauchow T; MacPherson P
    HIV Med; 2009 Oct; 10(9):548-54. PubMed ID: 19515092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil.
    Vergara TR; Estrela RC; Suarez-Kurtz G; Schechter M; Cerbino-Neto J; Barroso PF
    Ther Drug Monit; 2006 Apr; 28(2):175-9. PubMed ID: 16628127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.
    Taylor S; van Heeswijk RP; Hoetelmans RM; Workman J; Drake SM; White DJ; Pillay D
    AIDS; 2000 Sep; 14(13):1979-84. PubMed ID: 10997403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.
    Else LJ; Taylor S; Back DJ; Khoo SH
    Antivir Ther; 2011; 16(8):1149-67. PubMed ID: 22155899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
    Cusini A; Vernazza PL; Yerly S; Decosterd LA; Ledergerber B; Fux CA; Rohrbach J; Widmer N; Hirschel B; Gaudenz R; Cavassini M; Klimkait T; Zenger F; Gutmann C; Opravil M; Günthard HF;
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):28-35. PubMed ID: 23018371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.
    Loutfy MR; Walmsley SL; Klein MB; Raboud J; Tseng AL; Blitz SL; Pick N; Conway B; Angel JB; Rachlis AR; Gough K; Cohen J; Haase D; Burdge D; Smaill FM; de Pokomandy A; Loemba H; Trottier S; la Porte CJ
    BMC Infect Dis; 2013 Jun; 13():256. PubMed ID: 23732043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal comparison between plasma and seminal HIV-1 viral loads during antiretroviral treatment.
    Pinto Neto LF; Vieira NF; Soprani M; Cunha CB; Cabral VP; Dietze R; Ribeiro-Rodrigues R
    Rev Soc Bras Med Trop; 2003; 36(6):689-94. PubMed ID: 15049108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission.
    Eron JJ; Vernazza PL; Johnston DM; Seillier-Moiseiwitsch F; Alcorn TM; Fiscus SA; Cohen MS
    AIDS; 1998 Oct; 12(15):F181-9. PubMed ID: 9814860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study.
    Vernazza PL; Troiani L; Flepp MJ; Cone RW; Schock J; Roth F; Boggian K; Cohen MS; Fiscus SA; Eron JJ
    AIDS; 2000 Jan; 14(2):117-21. PubMed ID: 10708281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.
    Poirier JM; Robidou P; Jaillon P
    Ther Drug Monit; 2005 Apr; 27(2):186-92. PubMed ID: 15795650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors.
    Gupta P; Mellors J; Kingsley L; Riddler S; Singh MK; Schreiber S; Cronin M; Rinaldo CR
    J Virol; 1997 Aug; 71(8):6271-5. PubMed ID: 9223532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men.
    Taylor S; Reynolds H; Sabin CA; Drake SM; White DJ; Back DJ; Pillay D
    AIDS; 2001 Oct; 15(15):2051-3. PubMed ID: 11600838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
    Bernal E; Masiá M; Padilla S; Ramos JM; Martín-Hidalgo A; Gutiérrez F
    Med Clin (Barc); 2007 Jul; 129(7):252-4. PubMed ID: 17683706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.